Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients With Relapsed/Refractory Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients With Relapsed Refractory Hodgkin Lymphoma
Clin. Cancer Res 2020 Oct 14;[EPub Ahead of Print], F Janku, H Park, SG Call, K Madwani, Y Oki, V Subbiah, DS Hong, A Naing, VM Velez-Bravo, TG Barnes, FB Hagemeister, GS Falchook, DD Karp, JJ Wheler, SA Piha-Paul, I Garrido-Laguna, EJ Shpall, LE Fayad, SS Neelapu, F Meric-Bernstam, R Kurzrock, MA FanaleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.